A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
<p><strong>Background</strong> BRCA1 and BRCA2 genes are critical in homologous recombination DNA repair and have been implicated in familial breast and ovarian cancer tumorigenesis. Tumour cells with these mutations demonstrate increased sensitivity to cisplatin and poly (ADP-ribo...
Main Authors: | Nicum, S, Roberts, C, Boyle, L, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Poole, C, Collins, L, Schuh, A, Dutton, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2014
|
Similar Items
-
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
by: Roberts, C, et al.
Published: (2019) -
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
by: Nicum, S, et al.
Published: (2013) -
6-Mercaptopurine Or Azathioprine?
by: McGovern, D, et al.
Published: (2007) -
Effect of maintenance therapy for childhood with acute lymphoblastic leukaemia by combination of methotrexate and 6–mercaptopurine on the liver.
by: Abid T. Firas, et al.
Published: (2005-12-01) -
Cytotoxicity effect of 6-mercaptopurine and 6-mercaptopurine riboside on RAW 264.7 and HIG-82 cell lines
by: Che Ku Daud, Che Ku Dahlan, et al.
Published: (2014)